PF-06273340 is a research small molecule developed for studies focused on tropomyosin-related kinase signaling. In technical catalogs and procurement workflows, it is commonly identified by CAS 1402438-74-7 and linked with the naming variants PF-06273340 Pfizer and Pfizer PF-06273340. This compound has gained attention in discovery programs where scientists need a selective Trk-directed tool molecule supported by clear reference data, defined structure information, and documented biological performance. According to supplier technical documentation, PF-06273340 molecular formula is C23H22ClN7O3 and its molecular weight is 479.92, making these descriptors important for identity confirmation, registration, and cross-platform compound matching. PF-06273340 chemical structure is therefore not just a search phrase, but a practical checkpoint in research sourcing and assay planning.
Application of PF-06273340
In research settings, PF-06273340 is used in studies of neurotrophin signaling, receptor tyrosine kinase biology, pain-related pathways, and target validation. Because Trk receptors influence neuronal survival, sensory signaling, and adaptive cellular responses, this molecule is relevant for experiments that investigate kinase inhibition in both mechanistic and translational contexts. It is also useful in screening cascades where investigators compare selective kinase inhibitors with broader pathway modulators. For product pages such as EBC-221082, that application profile matters because scientists often need more than a name and catalog number - they need enough biological context to understand how the molecule may fit a specific panel, pathway, or disease-focused workflow.
Biological Activity
Published supplier descriptions characterize PF-06273340 as a potent and selective pan-Trk inhibitor. Reported IC50 values are 1 nM for TrkC, 2 nM for TrkB, and 6 nM for TrkA. Technical references also note that the compound is selective for Trk over a broader panel of ion channels, receptors, and enzymes. This selectivity profile is one of the main reasons it remains relevant in target-focused pharmacology, especially when teams need a defined inhibitor for pathway interrogation instead of a less selective kinase tool. In addition, reference pages describe the compound as orally bioavailable and active in a rodent model of inflammatory pain.
Biochemical and Physiological Actions
At the biochemical level, PF-06273340 modulates Trk receptor signaling and supports the study of downstream processes connected to neurotrophin-driven cellular communication. Physiologically, this is important in models where Trk activity is linked to pain signaling and receptor-mediated neuronal responses. One point worth noting is that different supplier pages emphasize different properties, with Tocris describing the molecule as peripherally restricted, while Sigma-Aldrich describes it as brain penetrant. That difference makes clear product communication especially valuable for buyers reviewing PF-06273340 chemical structure and activity together before selecting a source for research use.
Features and Benefits of PF-06273340
- Defined identifiers, including CAS 1402438-74-7, PF-06273340 molecular formula, and documented structure data
- Potent pan-Trk inhibition with reported nanomolar activity across TrkA, TrkB, and TrkC
- Strong fit for screening, validation, and pathway-focused research requiring a selective Trk inhibitor
For discovery teams evaluating EBC-221082, PF-06273340 offers a combination of technical clarity and research relevance that supports confident compound selection in kinase biology and pain-related studies.
